Biocon Limited — Q1 FY25
Biocon's Q1 FY25 revenue from operations was flat YoY at INR 3,433 crore, with adjusted EBITDA of INR 698 crore (20% margin) and adjusted PAT of INR 19 crore.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q4 FY24
Biosimilars R&D spend 8%-9% of revenues
Biocon Biologics expects R&D investments to be in the 8%-9% of revenues range.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1